Walgreens Boots Alliance (WBA) Stock Slides as Market Rises: Facts to Know Before You Trade

Walgreens Boots Alliance (WBA) underperformed the broader market, closing at $11.20 (-0.44%) while the S&P 500 gained 0.41%. The company's stock has also underperformed the Retail-Wholesale sector and S&P 500 over the past month. WBA's upcoming earnings report is projected to show a 46.03% year-over-year decline in earnings per share, though revenue is expected to increase slightly; full-year earnings are projected to decline by 42.36%.

Analysis

Walgreens Boots Alliance (WBA) shares closed at $11.20, a decline of 0.44%, underperforming the S&P 500's 0.41% gain on the same day. Over the past month, WBA's 2.46% appreciation has also trailed the Retail-Wholesale sector's 5.64% increase and the S&P 500's 6.13% rise. The company faces a challenging outlook for its upcoming earnings report, with projections indicating a substantial 46.03% year-over-year decrease in earnings per share to $0.34, despite an anticipated slight revenue increase of 0.85% to $36.66 billion. Full-year estimates also point to a significant earnings contraction, with projected EPS of $1.66 representing a 42.36% decline from the previous year, although full-year revenue is expected to grow by 2.59% to $151.49 billion. Analyst consensus EPS projections for WBA have remained stagnant over the past 30 days, contributing to its current Zacks Rank of #3 (Hold). From a valuation perspective, WBA's Forward P/E ratio of 6.77 is at a premium to its industry's average of 5.43, and its PEG ratio of 1.35 is notably higher than the industry average of 0.79, suggesting potentially less attractive growth prospects relative to its earnings multiple. Despite these company-specific headwinds, the broader Retail - Pharmacies and Drug Stores industry, to which WBA belongs, holds a strong Zacks Industry Rank of 3, placing it in the top 2% of over 250 industries.

Key Decisions for Investors

• Investors should closely monitor Walgreens Boots Alliance's upcoming earnings report for any deviation from the sharply negative EPS projections and for management's commentary on future profitability.
• The current valuation, reflecting a premium Forward P/E and a high PEG ratio compared to industry peers alongside stagnant EPS estimates, suggests caution may be warranted pending clearer signs of a turnaround.
• Given the Zacks Rank #3 (Hold) and significant anticipated earnings decline, consider maintaining current positions or awaiting further data post-earnings before initiating new ones, despite the underlying strength in the broader retail pharmacy sector.